This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Brunton LL, Lazo JS, Parker KL, Eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. New York, NY, USA: The McGraw-Hill Companies Inc., 2006.BruntonLLLazoJSParkerKLGoodman and Gilman’s The Pharmacological Basis of Therapeutics11th edNew York, NY, USAThe McGraw-Hill Companies Inc2006Search in Google Scholar
Ritter JM, Lewis LD, Mant TG, Ferro A, Eds. A Textbook of Clinical Pharmacology and Therapeutics, 5th ed. London, UK: Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 2008.RitterJMLewisLDMantTGFerroAA Textbook of Clinical Pharmacology and Therapeutics5th edLondon, UKHodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK200810.1201/b13234Search in Google Scholar
Wells BG, Dipiro JT, Schwinghammer TL, Dipiro CV, Eds. Pharmacotherapy Handbook, 7th ed. New York, NY, USA: The McGraw-Hill Companies, Inc., 2009.WellsBGDipiroJTSchwinghammerTLDipiroCVPharmacotherapy Handbook7th edNew York, NY, USAThe McGraw-Hill Companies, Inc2009Search in Google Scholar
Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Disposition. 2011; 39(5): 927-932.Tomalik-ScharteDFuhrUHellmichMFrankDDoroshyenkoOet al.Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinideDrug Metab Disposition201139592793210.1124/dmd.110.03692121270106Search in Google Scholar
Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers. 2012; 16(7): 812-816.PechandovaKBuzkovaHMatouskovaOPerlikFSlanarO.Genetic polymorphisms of CYP2C8 in the Czech RepublicGenet Test Mol Biomarkers201216781281610.1089/gtmb.2011.0275339600522313047Search in Google Scholar
Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008; 3(1): 7-16.AquilanteCLBushmanLRKnutsenSDBurtLERomeLCKosmiskiLA.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersHum Genomics20083171610.1186/1479-7364-3-1-7352517819129086Search in Google Scholar
Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J Toxicol Sci. 2009; 34(2): 307-312.YokoiT.Essentials for starting a pediatric clinical study (1): Pharmacokinetics in childrenJ Toxicol Sci200934230731210.2131/jts.34.SP307Search in Google Scholar
Cella M, Knibbe C, Danhof M, Pasqua OD. What is the right dose for children. Br J Clin Pharmacol. 2010; 70(4): 597-603.CellaMKnibbeCDanhofMPasquaOD.What is the right dose for childrenBr J Clin Pharmacol201070459760310.1111/j.1365-2125.2009.03591.x295099421087295Search in Google Scholar
Djordjevic N, Milovanovic DD, Radovanovic M, Radosavljevic I, Obradovic S, Jakovljevic M, et al. CYP1 A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. Eur J Clin Pharmacol. 2016; 72(4): 439-445.DjordjevicNMilovanovicDDRadovanovicMRadosavljevicIObradovicSJakovljevicMet al.CYP1 A2 genotype affects carbamazepine pharmacokinetics in children with epilepsyEur J Clin Pharmacol201672443944510.1007/s00228-015-2006-926762380Search in Google Scholar
Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2008; 30(9): 707-713.JankovicSMJovanovicDMilovanovicJR.Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patientsMethods Find Exp Clin Pharmacol200830970771310.1358/mf.2008.30.9.1323496Search in Google Scholar
Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphism of CYP2 C8 in Japaneze population. Drug Metab Dispos. 2003; 31(6): 687-690.NakajimaMFujikiYNodaKOhtsukaHOhkuniHKyoSet al.Genetic polymorphism of CYP2 C8 in Japaneze populationDrug Metab Dispos200331668769010.1124/dmd.31.6.68712756196Search in Google Scholar
Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Phar-macogenet Genomics. 2013; 23(12): 721-728.AquilanteCLNiemiMGongLAltmanRBKleinTE.PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8Phar-macogenet Genomics2013231272172810.1097/FPC.0b013e3283653b27403862623962911Search in Google Scholar
Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005; 33(5): 630-636.HichiyaHTanaka-KagawaTSoyamaAJinnoHKoyanoSKatoriNet al.Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese populationDrug Metab Dispos200533563063610.1124/dmd.105.003830Search in Google Scholar
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharma-cogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92(4): 414-417.Whirl-CarrilloMMcDonaghEMHebertJMGongLSangkuhlKThornCFet al.Pharma-cogenomics knowledge for personalized medicineClin Pharmacol Ther201292441441710.1038/clpt.2012.96Search in Google Scholar
Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol. 2005; 68(3): 747-757.FergusonSSChenYLeCluyseELNegishiMGoldsteinJA.Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alphaMol Pharmacol200568374775710.1124/mol.105.013169Search in Google Scholar
Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated with car-bamazepine. Clin Pharmacol Ther. 2006; 80(5): 440-456.OscarsonMZangerUMRifkiOFKleinKEichelbaumMMeyerUA.Transcriptional profiling of genes induced in the livers of patients treated with car-bamazepineClin Pharmacol Ther200680544045610.1016/j.clpt.2006.08.013Search in Google Scholar
Owen A, Goldring C, Morgan P, Park BK, Pirmohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: The role of nuclear hormone response elements. Br J Clin Pharmacol. 2006; 62(2): 237-242.OwenAGoldringCMorganPParkBKPirmohamedM.Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: The role of nuclear hormone response elementsBr J Clin Pharmacol200662223724210.1111/j.1365-2125.2006.02587.xSearch in Google Scholar
Thorn CF, Leckband SG, Kelsoe J, Leeder JS, Muller DJ, Klein TE, et al. PharmGKB summary: Car-bamazepine pathway. Pharmacogenet Genomics. 2011; 21(12): 906-910.ThornCFLeckbandSGKelsoeJLeederJSMullerDJKleinTEet al.PharmGKB summary: Car-bamazepine pathwayPharmacogenet Genomics2011211290691010.1097/FPC.0b013e328348c6f2Search in Google Scholar
Soyama A, Saito Y, Momamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metabol Pharmacokin. 2002; 17(4): 374-377.SoyamaASaitoYMomamuraKUenoKKamakuraSOzawaSet al.Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shiftDrug Metabol Pharmacokin200217437437710.2133/dmpk.17.374Search in Google Scholar
Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002; 64(11): 1579-1589.BahadurNLeathartJBMutchESteimel-CrespiDDunnSAGilissenRet al.CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomesBiochem Pharmacol200264111579158910.1016/S0006-2952(02)01354-0Search in Google Scholar
Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003; 74(4): 380-387.NiemiMLeathartJBNeuvonenMBackmanJTDalyAKNeuvonenPJ.Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinideClin Pharmacol Ther200374438038710.1016/S0009-9236(03)00228-5Search in Google Scholar
Martínez C, García-Martín E, Blanco G, Gamito FJG, Ladero JM, Agúndez JAG. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2004; 59(1): 62-68.MartínezCGarcía-MartínEBlancoGGamitoFJGLaderoJMAgúndezJAG.The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjectsBr J Clin Pharmacol2004591626810.1111/j.1365-2125.2004.02183.x188495915606441Search in Google Scholar
Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther. 2006; 80(6): 657-667.KirchheinerJThomasSBauerSTomalik-ScharteDHeringUDoroshyenkoOet al.Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeClin Pharmacol Ther200680665766710.1016/j.clpt.2006.09.00817178266Search in Google Scholar
Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2 C8 *3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011; 11(2): 113-120.BergmannTKBrasch-AndersenCGreenHMirzaMPedersenRSNielsenFet al.Impact of CYP2 C8 *3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerPharmacogenomics J201111211312010.1038/tpj.2010.1920368717Search in Google Scholar
Wójcikowski J, Basinska A, Daniel WA. The cytochrome P450-catalyzed metabolism of levomepromazine: A phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol. 2014; 90(2): 188-195.WójcikowskiJBasinskaADanielWA.The cytochrome P450-catalyzed metabolism of levomepromazine: A phenothiazine neuroleptic with a wide spectrum of clinical applicationBiochem Pharmacol201490218819510.1016/j.bcp.2014.05.00524841887Search in Google Scholar
Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies. Pharmacogenomics. 2009; 10(9): 1489-1510.DailyEBAquilanteCL.Cytochrome P450 2C8 pharmacogenetics: A review of clinical studiesPharmacogenomics20091091489151010.2217/pgs.09.82277805019761371Search in Google Scholar
Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol. 2011; 82(6): 681-691.KasperaRNaraharisettiSBEvangelistaEAMarcianteKDPsatyBMTotahRA.Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5Biochem Pharmacol201182668169110.1016/j.bcp.2011.06.027315954821726541Search in Google Scholar
Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit. 1994; 16(5): 469-476.LiuHDelgadoMR.Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolitesTher Drug Monit199416546947610.1097/00007691-199410000-000057846744Search in Google Scholar
Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol. 1998; 54(4): 359-362.GrayALBothaJHMillerR.A model for the determination of carbamazepine clearance in children on mono- and polytherapyEur J Clin Pharmacol199854435936210.1007/s0022800504759696965Search in Google Scholar
Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol. 2001; 51(6): 567-576ChanELeeHSHueSS.Population pharmacokinetics of carbamazepine in Singapore epileptic patientsBr J Clin Pharmacol200151656757610.1046/j.0306-5251.2001.01396.x201449411422016Search in Google Scholar
Deleu D, Aarons L, Ahmed I. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol. 2001; 57(3): 243-248.DeleuDAaronsLAhmedI.Population pharmacokinetics of free carbamazepine in adult Omani epileptic patientsEur J Clin Pharmacol200157324324810.1007/s00228010030011497340Search in Google Scholar
Jiao Z, Shi XJ, Zhao ZG, Zhong MK. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther. 2004; 29(3): 247-256.JiaoZShiXJZhaoZGZhongMK.Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical dataJ Clin Pharm Ther200429324725610.1111/j.1365-2710.2004.00557.x15153086Search in Google Scholar
Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11 -epoxide serum concentrations in epileptic children. J Pediatr. 1985; 106(3): 491-495.FurlanutMMontanariGBoninPCasaraGL.Carbamazepine and carbamazepine-10,11 -epoxide serum concentrations in epileptic childrenJ Pediatr1985106349149510.1016/S0022-3476(85)80689-2Search in Google Scholar
Summers B, Summers RS. Carbamazepine clearance in pedetric epilepsy patients. Influence of both mass, dose, sex and co-medication. Clin Pharmacokin. 1989; 17(3): 208-216.SummersBSummersRS.Carbamazepine clearance in pedetric epilepsy patients. Influence of both mass, dose, sex and co-medicationClin Pharmacokin198917320821610.2165/00003088-198917030-000062805552Search in Google Scholar
Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn. 2001; 28(1): 79-92.ReithDMHooperWDParkeJCharlesB.Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adultsJ Pharmacokinet Pharmacodyn2001281799210.1023/A:1011569703060Search in Google Scholar
El Desoky ES, Sabarinath SN, Hamdi MM, Bewernitz M, Derendorf H. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther. 2012; 37(3): 352-355.El DesokyESSabarinathSNHamdiMMBewernitzMDerendorfH.Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patientsJ Clin Pharm Ther201237335235510.1111/j.1365-2710.2011.01296.x21883329Search in Google Scholar
Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J, et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin. 2014; 35(10): 1342-1350.WangYZhangHNNiuCHGaoPChenYJPengJet al.Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsyActa Pharmacol Sin201435101342135010.1038/aps.2014.76418699225220641Search in Google Scholar
Milovanovic JR, Jankovic SM. Factors influencing carbamazepine pharmacokinetics in children and adults: Population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2011; 49(7): 428-436.MilovanovicJRJankovicSM.Factors influencing carbamazepine pharmacokinetics in children and adults: Population pharmacokinetic analysisInt J Clin Pharmacol Ther201149742843610.5414/CP201517Search in Google Scholar
Delgado Iribarnegaray MF, Santo Bueldga D, García Sánchez MJ, Otero MJ, Falcão AC, Domínguez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 1997; 19(2): 132-139.Delgado IribarnegarayMFSanto BueldgaDGarcía SánchezMJOteroMJFalcãoACDomínguez-GilA.Carbamazepine population pharmacokinetics in children: Mixed-effect modelsTher Drug Monit199719213213910.1097/00007691-199704000-000039108639Search in Google Scholar
Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit. 2003;25(3):279-286.JiaoZZhongMKShiXJHuMZhangJH.Population pharmacokinetics of carbamazepine in Chinese epilepsy patientsTher Drug Monit200325327928610.1097/00007691-200306000-0000512766553Search in Google Scholar
